MGMT and neoplasm: Wiewrodt et al (Wiewrodt et al, 2008) showed that patients expressing ⩽30 fmol mg−1 MGMT protein in the pre-treatment tumour volume had a significantly better response to alkylating therapy than those with MGMT protein above this level.